The current US Supreme Court has no fundamental understanding of a range of medical, engineering, technological, or ...

The new indication will be another blow to Praluent’s PCSK9 inhibitor rival Repatha. Both drugs have been fighting it out after they were approved within a few weeks of each other in 2015.

The Dusseldorf Regional Court said late last week that Sanofi’s Praluent (alirocumab) infringes the German part of Amgen’s European patent directed to antibodies targeting PCSK9, which ...

These new therapies belong to a class of drugs known as PCSK9 inhibitors and have the potential to reduce the risk of heart attack and stroke for millions of Americans. However, the prices of these ...